Asthma is an inflammatory disease typified by airway hyperreactivity and obstruction-producing airway resistance with a reduction in air flow. [1] The mainstay of treatment of acute asthma in children ...
Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) This is an ASCO Meeting Abstract from the 2004 ...
TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...
Please provide your email address to receive an email when new articles are posted on . TNKase is the first stroke treatment approved by the FDA in almost 30 years, the manufacturer said. It is ...
Paricalcitol 2mcg/mL, 5mcg/mL; soln for IV inj; contains alcohol. Give as IV bolus inj during dialysis. Initially 0.04–0.1mcg/kg (2.8–7mcg) no more often than every other day; may increase in ...
The VE response to I.V. bolus infusion of Dox is largely unkown, although Dox is used parenterally in the treatment of apnea of infancy. The objectives of this study were 1) to determine if VE ...
Giving the bolus thrombolytic tenecteplase in a mobile stroke unit resulted in signs of improved efficacy compared with the standard of care thrombolytic alteplase, without any safety concerns, in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback